Cardinal Health and the University of Washington have announced a public-private collaboration to advance the use of molecular imaging in clinical investigations and trials.
Molecular imaging uses specialised radiopharmaceuticals, or positron emission tomography (PET) imaging agents, to detect and trace abnormal cellular functions associated with heart disease, neurological disorders and many forms of cancer.
These imaging agents, which are visible using sophisticated imaging scanners, allow physicians to non-invasively diagnose, monitor and potentially treat diseases at early stages.
The University of Washington will combine their PET research and development expertise with Cardinal Health’s knowledge in the FDA-compliant production and distribution of PET imaging agents to accelerate the research, development and commercialisation of new molecular imaging agents.
